Fragment screening by biochemical assay

The use of high concentration biochemical assays to identify weak binding fragment molecules can be an effective method to identify novel starting points for medicinal chemistry programmes. The combination of a high-quality fragment library with sensitive biochemical screening methods is a viable alternative to the more commonly used fragment screening methods such as nuclear magnetic resonance screening or high-throughput X-ray crystallography. Notably, there are a number of literature reports where fragment molecules have been identified by a high concentration biochemical assay. The use of high concentration screening of fragments using a portfolio of single-molecule fluorescence correlation spectroscopy detection techniques to ensure the highest reproducibility and sensitivity have been demonstrated, as well as the use of and X-ray crystallography to determine the binding mode of active fragments.

[1]  Vicki L. Nienaber,et al.  Discovering novel ligands for macromolecules using X-ray crystallographic screening , 2000, Nature Biotechnology.

[2]  B R Baker,et al.  Irreversible enzyme inhibitors. CVI. Proteolytic enzymes. I. Bulk tolerances in trypsin-inhibitor complexes. , 1967, Journal of medicinal chemistry.

[3]  M. Congreve,et al.  Fragment-based lead discovery , 2004, Nature Reviews Drug Discovery.

[4]  J. Ellman,et al.  Substrate activity screening: a fragment-based method for the rapid identification of nonpeptidic protease inhibitors. , 2005, Journal of the American Chemical Society.

[5]  Jeremy R Everett,et al.  NanoStore: A Concept for Logistical Improvements of Compound Handling in High-Throughput Screening , 2005, Journal of biomolecular screening.

[6]  Dustin J Maly,et al.  Combinatorial target-guided ligand assembly: identification of potent subtype-selective c-Src inhibitors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Robert Schweitzer,et al.  Comparison of Assay Technologies for a Tyrosine Kinase Assay Generates Different Results in High Throughput Screening , 2002, Journal of biomolecular screening.

[8]  William W. Cohen,et al.  Studies on the Active Center of Trypsin , 2003 .

[9]  T. Gadek,et al.  Discovery of novel PTP1b inhibitors. , 2004, Bioorganic & medicinal chemistry letters.

[10]  Bohdan Waszkowycz,et al.  PRO_SELECT: combining structure-based drug design and array-based chemistry for rapid lead discovery. 2. The development of a series of highly potent and selective factor Xa inhibitors. , 2002, Journal of medicinal chemistry.

[11]  Edward R Zartler,et al.  Fragonomics: fragment-based drug discovery. , 2005, Current opinion in chemical biology.

[12]  Andreas Sewing,et al.  Fluorescence readouts in HTS: no gain without pain? , 2003, Drug discovery today.

[13]  Jeffrey W. Peng,et al.  Theory and applications of NMR-based screening in pharmaceutical research. , 2004, Chemical reviews.

[14]  Kazuo Shinozaki,et al.  A structure‐based strategy for discovery of small ligands binding to functionally unknown proteins: Combination of in silico screening and surface plasmon resonance measurements , 2005, Proteomics.

[15]  C. Eggeling,et al.  New fluorescence techniques for high-throughput drug discovery. , 2003, Current pharmaceutical biotechnology.

[16]  M. Congreve,et al.  A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.

[17]  Gianni Chessari,et al.  Application of fragment screening and fragment linking to the discovery of novel thrombin inhibitors. , 2006, Journal of medicinal chemistry.

[18]  C. Craik,et al.  Design and synthesis of novel inhibitors of gelatinase B. , 2002, Bioorganic & medicinal chemistry letters.

[19]  B. Shoichet,et al.  A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. , 2002, Journal of medicinal chemistry.

[20]  C. Chung,et al.  Effect of detergent on "promiscuous" inhibitors. , 2003, Journal of medicinal chemistry.

[21]  J. T. Metz,et al.  Ligand efficiency indices as guideposts for drug discovery. , 2005, Drug discovery today.

[22]  Christian Eggeling,et al.  Highly sensitive fluorescence detection technology currently available for HTS. , 2003, Drug discovery today.

[23]  Nicola Mongelli,et al.  A general NMR method for rapid, efficient, and reliable biochemical screening. , 2003, Journal of the American Chemical Society.

[24]  Tudor I. Oprea,et al.  Pursuing the leadlikeness concept in pharmaceutical research. , 2004, Current opinion in chemical biology.

[25]  Jean M. Severin,et al.  Discovery of potent inhibitors of dihydroneopterin aldolase using CrystaLEAD high-throughput X-ray crystallographic screening and structure-directed lead optimization. , 2004, Journal of medicinal chemistry.

[26]  P. Hajduk,et al.  High-throughput nuclear magnetic resonance-based screening. , 1999, Journal of medicinal chemistry.

[27]  P. Hajduk,et al.  SOS-NMR: a saturation transfer NMR-based method for determining the structures of protein-ligand complexes. , 2004, Journal of the American Chemical Society.

[28]  D. Wyss,et al.  Competition STD NMR for the detection of high‐affinity ligands and NMR‐based screening , 2004, Magnetic resonance in chemistry : MRC.

[29]  Daniel A Erlanson,et al.  Making drugs on proteins: site-directed ligand discovery for fragment-based lead assembly. , 2004, Current opinion in chemical biology.

[30]  U. Haupts,et al.  Macroscopic versus microscopic fluorescence techniques in (ultra)-high-throughput screening , 2000 .

[31]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[32]  Matthew A. Cooper,et al.  Optical biosensors in drug discovery , 2002, Nature Reviews Drug Discovery.

[33]  Tudor I. Oprea,et al.  Is There a Difference between Leads and Drugs? A Historical Perspective , 2001, J. Chem. Inf. Comput. Sci..

[34]  E. Shaw,et al.  Studies on the active center of trypsin. Further characterization of the hydrophobic binding site. , 1967, The Journal of biological chemistry.

[35]  R. Liskamp,et al.  Surface plasmon resonance thermodynamic and kinetic analysis as a strategic tool in drug design. Distinct ways for phosphopeptides to plug into Src- and Grb2 SH2 domains. , 2005, Journal of medicinal chemistry.

[36]  D. Fattori,et al.  Molecular recognition: the fragment approach in lead generation. , 2004, Drug discovery today.

[37]  A. Sharff,et al.  High-throughput crystallography to enhance drug discovery. , 2003, Current opinion in chemical biology.

[38]  H. Matter,et al.  Custom chemical microarray production and affinity fingerprinting for the S1 pocket of factor VIIa. , 2004, Analytical biochemistry.

[39]  D. Kostrewa,et al.  Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. , 2000, Journal of medicinal chemistry.

[40]  Elena Conti,et al.  X‐ray and spectrophotometric studies of the binding of proflavin to the S1 specificity pocket of human α‐thrombin , 1998 .

[41]  P. Hajduk,et al.  Discovering High-Affinity Ligands for Proteins: SAR by NMR , 1996, Science.

[42]  Markus Schade,et al.  NMR fragment screening: Advantages and applications. , 2006, IDrugs : the investigational drugs journal.

[43]  Andrew R. Leach,et al.  Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery , 2001, J. Chem. Inf. Comput. Sci..

[44]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[45]  Nicola Mongelli,et al.  Sensitivity improvement in 19F NMR-based screening experiments: theoretical considerations and experimental applications. , 2005, Journal of the American Chemical Society.

[46]  K. Breuker New mass spectrometric methods for the quantification of protein-ligand binding in solution. , 2004, Angewandte Chemie.

[47]  Dustin J Maly,et al.  Tyrosylprotein sulfotransferase inhibitors generated by combinatorial target-guided ligand assembly. , 2002, Bioorganic & medicinal chemistry letters.

[48]  Hugo O Villar,et al.  Using NMR for ligand discovery and optimization. , 2004, Current opinion in chemical biology.

[49]  Christopher W Murray,et al.  Fragment-based lead discovery using X-ray crystallography. , 2005, Journal of medicinal chemistry.

[50]  D. Vetter Chemical microarrays, fragment diversity, label‐free imaging by plasmon resonance—a chemical genomics approach , 2002, Journal of cellular biochemistry. Supplement.

[51]  B. Shoichet,et al.  A specific mechanism of nonspecific inhibition. , 2003, Journal of medicinal chemistry.

[52]  Brian Dymock,et al.  Design and Characterization of Libraries of Molecular Fragments for Use in NMR Screening against Protein Targets , 2004, J. Chem. Inf. Model..

[53]  Jeffrey W. Peng,et al.  Applications of SHAPES screening in drug discovery. , 2002, Combinatorial chemistry & high throughput screening.

[54]  B. Shoichet,et al.  Identification and prediction of promiscuous aggregating inhibitors among known drugs. , 2003, Journal of medicinal chemistry.

[55]  Christopher W Murray,et al.  Fragment-based lead discovery: leads by design. , 2005, Drug discovery today.

[56]  Edgar Jacoby,et al.  Library design for fragment based screening. , 2005, Current topics in medicinal chemistry.

[57]  Manfred Auer,et al.  Fluorescence correlation spectroscopy: Lead discovery by miniaturized HTS , 1998 .

[58]  J Fraser Glickman,et al.  Comparison of Assay Technologies for a Nuclear Receptor Assay Screen Reveals Differences in the Sets of Identified Functional Antagonists , 2003, Journal of biomolecular screening.

[59]  Wolfgang Jahnke,et al.  Second-site NMR screening and linker design. , 2003, Current topics in medicinal chemistry.

[60]  Christian Eggeling,et al.  Experiences in implementing uHTS--cutting edge technology meets the real world. , 2004, Current drug discovery technologies.

[61]  T. Gadek,et al.  Structure-activity relationships by mass spectrometry: identification of novel MMP-3 inhibitors. , 2004, Bioorganic & medicinal chemistry.

[62]  Kam Y. J. Zhang,et al.  A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design , 2005, Nature Biotechnology.

[63]  Gang Liu,et al.  Discovery of a potent, selective protein tyrosine phosphatase 1B inhibitor using a linked-fragment strategy. , 2003, Journal of the American Chemical Society.